Pharmacokinetics in Morbid Obesity After Bariatric Surgery
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Morbid obesity (MO) is associated with several disorders such as hypertension, type 2
diabetes, dyslipemia and degenerative arthropathy that require pharmacological treatment.
Drug bioavailability and metabolism in patients with MO is altered compared to population
controls. Bariatric surgery is the gold standard treatment for MO when conventional therapy
fails.
Bariatric surgery techniques can modify drug absorption in MO patients. These modifications
depend on the drug absorption characteristics and on the bariatric surgery technique used.
The changes in weight and body composition caused by BS at middle term can alter drug
bioavailability and metabolism. The kinetics of the "normalization" process in patients with
MO after bariatric surgery is unknown
Objectives. To analyze the changes in drug metabolism and pharmacokinetics. To establish drug
dosing criteria in the post-intervention period in patients with MO after bariatric surgery.
To determine the relationship between changes in drug bioavailability and metabolism in MO
after bariatric surgery (longitudinal gastrectomy and Y-roux gastric by-pass).